Overview

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to placebo in the treatment of atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer